The pharmaceutical industry seems besieged on all sides, with declining R&D productivity, expiring patents on blockbuster products and relentless downward pricing pressure forcing companies to look closely at the bottom line. One affect of this onslaught has been an upsurge in the level of M&A activity as players within the industry consolidate to cut costs, expand research pipelines and lengthen geographic reach.
25-Aug-2015 - Mylan will run Perrigo as a wholly-owned subsidiary if it acquires between 50-80% of shares, the firm has clarified.
24-Aug-2015 - Pfizer has received the final regulatory clearances to acquire Hospira but the US FTC says it must divests four sterile injectable products.
17-Aug-2015 - An SEC filing reveals Merck has cut 29,160 jobs in five years, and over 2,500 more may be on the way.
17-Aug-2015 - The huge former Ben Venue injectables manufacturing plant in Ohio that became the center of controversy over drug shortages a few years ago remains off line, and the company that...
30-Jul-2015 - Industry headhunters have picked their top CEOs in European pharma, saying the most successful investors keep chief execs in place even through hard times.
28-Jul-2015 - Hikma says its $2.65bn acquisition of Roxane Laboratories will make it the sixth largest firm in the US generics space.
27-Jul-2015 - Teva has struck a deal to buy Allergan’s generics business a week after its persistent attempts to acquire Mylan fell through.
21-Jul-2015 - Celgene will take over a Merck & Co. facility in Summit, New Jersey which had been earmarked for closure.
20-Jul-2015 - Torrent Pharma has added two facilities to its network through the acqusition of Zyg Pharma from the Encore Group.
16-Jul-2015 - Celgene has shelled out $7.2bn (€6.6bn) to acquire Receptos which is developing an oral lymphocyte trafficking agent for multiple sclerosis and inflammatory bowel disorder.
30-Jun-2015 - The proposed Perrigo merger with Mylan would be of no benefit to either firm in the “highly competitive” OTC sector, according to financial analysts BMO.
25-Jun-2015 - Demand for CNS assets will help break records for pharma M&As in 2015, Neel Patel, VP of inVentiv Health consultancy Campbell Alliance, tells in-Pharmatechnologist.com.
18-Jun-2015 - Ex-Allergan CEO David Pyott has spoken of his “total war” battling Valeant’s failed hostile takeover, and given advice to other pharmaceutical companies on how to deal with activist shareholders.
08-Jun-2015 - Teva has refuted accusations of “meddling” with Mylan’s business in the latest chapter of what one analyst says is a far from friendly, if not hostile takeover attempt.
02-Jun-2015 - Teva has been accused of "playing games" with Mylan by acquiring a 1.35% stake in the generics firm weeks after having a $40bn (EUR36bn) takeover bid snubbed....
28-May-2015 - Merck KGaA is confident it will close the $17bn acquisition of Sigma-Aldrich in mid-2015 despite competition concerns from the European Commission (EC).
19-May-2015 - Endo’s $8bn takeover of Par Pharmaceutical is expected to shake-up the generics sector, while Lupin is expanding its South American network – welcome to In-Pharmatechnologist’s M&A round-up.
18-May-2015 - Pfizer is set to close its $17bn (€15bn) acquisition by the end of the year after receiving the thumbs up from Hospira shareholders.
07-May-2015 - BASF says it remains committed to the pharma industry despite plans to divest its custom synthesis business and around 100 APIs and intermediates to Siegfried Holding.
06-May-2015 - AMRI attributed a robust first quarter to its growing API business and recent acquisitions, and says to expect more M&A activity this year.
28-Apr-2015 - Mylan has rejected an unsolicited bid by Teva and upped its offer for Perrigo, as the ongoing saga in the generics space continues.
23-Apr-2015 - Pfizer reduced costs 40% without cutting jobs at a facility in Sweden using an alternative approach to organisational and cultural behaviour, and hopes to do the same at its newly acquired Austrian...
21-Apr-2015 - A merger with Mylan would “transform the global generics space” says Teva, which has entered a $40bn bid as an alternative to the recently proposed Mylan-Perrigo deal.
21-Apr-2015 - Almost 600 staff at Allergan’s headquarters in Irvine, California, will be laid off in the Botox maker’s latest round of job cuts.
09-Apr-2015 - Mylan has bid $29bn (€27bn) to buy Perrigo in what the firm says will create a company with “unrivalled” manufacturing and supply chain capabilities across OTCs, generics and APIs.